Skip to main content
. 2017 Nov 5;19(12):982–990. doi: 10.1016/j.neo.2017.09.006

Supplementary Figure 2.

Supplementary Figure 2

(A) EFS and OS of 150 patients stratified according to a genomic copy number–based classification as proposed by Janoueix-Lerosey and coworkers [14]. (B) EFS and OS of patients with segmental copy number alterations (n = 88) stratified according to the NB-Risk Score. LR, low risk; IR, intermediate risk; HR, high risk.